Group 1 - The innovative drug sector experienced a significant upward trend on February 4, with notable gains in several companies [2] - HaiTe Bio saw an increase of over 8%, while GuangShengTang rose by more than 6% [2] - Other companies such as KangChen Pharmaceutical, ShuTaiShen, XinLiTai, BeiLu Pharmaceutical, and Tigermed also showed positive movement in their stock prices [2]

Group 1 - The A-share market saw a rise in innovative drug concept stocks, with notable increases in companies such as Haitai Biological (up over 8%), Guangshengtang (up 7%), and Kangchen Pharmaceutical (up over 5%) [1] - The National Medical Products Administration announced strong support for the innovation and development of the biomanufacturing industry during the "14th Five-Year Plan" period, aiming to shift the pharmaceutical industry from "follow-up innovation" to "systematic innovation" [1] Group 2 - Haitai Biological reported a rise of 8.63% with a total market value of 42.85 billion and a year-to-date increase of 18.07% [2] - Guangshengtang increased by 7.01%, with a total market value of 18.4 billion and a year-to-date increase of 29.53% [2] - Kangchen Pharmaceutical rose by 5.46%, with a total market value of 6.607 billion and a year-to-date increase of 4.53% [2] - Xintai increased by 4.20%, with a total market value of 53.6 billion and a year-to-date decrease of 2.89% [2] - Shutaishen and Beilu Pharmaceutical both saw increases of over 3%, with market values of 13 billion and 5.843 billion respectively [2]

1月30日，舒泰神涨0.63%，成交额3.95亿元。两融数据显示，当日舒泰神获融资买入额2081.25万元， 融资偿还1760.02万元，融资净买入321.23万元。截至1月30日，舒泰神融资融券余额合计1.33亿元。 融资方面，舒泰神当日融资买入2081.25万元。当前融资余额1.33亿元，占流通市值的1.08%。 融券方面，舒泰神1月30日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00元；融 券余量0.00股，融券余额0.00元。 资料显示，舒泰神(北京)生物制药股份有限公司位于北京市北京经济技术开发区经海二路36号，成立日 期2002年8月16日，上市日期2011年4月15日，公司主营业务涉及主要从事生物制品和部分化学药品的研 发、生产和销售。主营业务收入构成为：注射用鼠神经生长因子(苏肽生)59.17%，复方聚乙二醇电解质 散33.19%，其他7.63%。 截至9月30日，舒泰神股东户数4.65万，较上期增加46.97%；人均流通股9745股，较上期减少31.98%。 2025年1月-9月，舒泰神实现营业收入1.81亿元，同比减少30.82%；归母净利润-3068.95万元 ...

Core Viewpoint - The company Shuyou Shen (300204) anticipates a significant net loss for the fiscal year 2025, with projected losses ranging from 69.81 million to 85.33 million yuan, indicating a challenging financial outlook due to external factors and industry policies [1] Financial Performance - The expected net profit, excluding non-recurring gains and losses, is projected to be between 74.09 million and 90.56 million yuan [1] - The anticipated operating revenue is estimated to be between 198 million and 242 million yuan, a decrease from the previous year's revenue of 325 million yuan [1] - After adjustments, the operating revenue is also expected to fall within the same range of 198 million to 242 million yuan [1] Business Operations - The company reports that its production and operational activities are normal, with slight growth in sales revenue and volume for its product Su Tai [1] - However, the revenue from the product Shuyou Qing has declined due to external environmental factors and industry policies [1] Market Expansion - The company is actively working to expand its market for polyethylene glycol series products [1] - The expected non-recurring gains and losses for the fiscal year 2025 are approximately 4.75 million yuan [1]

证券日报网讯 1月28日，舒泰神发布公告称，公司预计2025年度营业收入19，830.77万元至24，237.61 万元，上年同期为32，481.60万元；归属于上市公司股东的净利润为-8，532.76万元至-6，981.35万元， 上年同期亏损14，484.26万元。 （文章来源：证券日报） ...

舒泰神表示，报告期内，公司生产经营活动正常，公司积极开展各项营销和市场探索工作，苏肽生产品 销售收入及销量均略有增长。此外，报告期内，受外部环境及行业政策等因素影响，公司产品舒泰清收 入有所下降；公司已在多渠道布局舒泰清产品市场探索，并着力于拓展聚乙二醇类系列产品的营销工 作。 北京商报讯（记者 丁宁）1月28日晚间，舒泰神（300204）发布2025年业绩预告显示，预计2025年实现 归属净利润-6981.35万元至-8532.76万元。 ...

Core Viewpoint - The company Shutaishen (300204.SZ) expects a net profit attributable to shareholders in 2025 to be between -85.33 million and -69.81 million yuan, with a net profit excluding non-recurring gains and losses estimated between -90.56 million and -74.09 million yuan, and operating revenue projected to be between 198.31 million and 242.38 million yuan [1] Group 1 - During the reporting period, the company's production and operational activities were normal, and it actively engaged in various marketing and market exploration efforts, resulting in slight growth in sales revenue and volume of the product Su Tai [1] - The revenue from the product Shutaqing decreased due to external environment and industry policy factors; the company is exploring multiple channels for the Shutaqing product market and focusing on expanding the marketing efforts for polyethylene glycol series products, including "Compound Polyethylene Glycol (3350) Electrolyte Powder (Shusitong)," "Compound Polyethylene Glycol (3350) Electrolyte Oral Solution (Shuyi Qing)," and "Compound Polyethylene Glycol (3350) Electrolyte Vitamin C Powder (Shuchang Qing)" [1] - The company expects non-recurring gains and losses for the year 2025 to be approximately 4.75 million yuan, with specific data to be disclosed in the 2025 annual report [1]

Core Viewpoint - The company Shutaishen (300204.SZ) expects a net profit attributable to shareholders in 2025 to be between -85.33 million and -69.81 million yuan, indicating a challenging financial outlook for the upcoming year [1] Financial Performance - The company anticipates a net profit excluding non-recurring gains and losses to range from -90.56 million to -74.09 million yuan for 2025 [1] - Projected operating revenue for the same period is estimated to be between 198.31 million and 242.38 million yuan [1] Business Operations - During the reporting period, the company's production and operational activities were normal, with a slight increase in sales revenue and volume for the product Su Tai [1] - The revenue from the product Shutaqing has decreased due to external environmental factors and industry policies, prompting the company to explore multiple channels for market expansion [1] Product Development - The company is focusing on marketing efforts for its polyethylene glycol series products, including "Compound Polyethylene Glycol (3350) Electrolyte Powder (Shu Sitong)," "Compound Polyethylene Glycol (3350) Electrolyte Oral Solution (Shu Yiqing)," and "Compound Polyethylene Glycol (3350) Electrolyte Vitamin C Powder (Shu Changqing)" [1] Non-recurring Gains and Losses - The company expects non-recurring gains and losses for 2025 to be approximately 4.75 million yuan, with specific figures to be disclosed in the annual report [1]

Financial Projections - The company expects a net profit of approximately -85.33 million CNY for the year 2025, compared to -69.81 million CNY in the same period last year[4]. - Revenue for the year 2025 is projected to be around 198.31 million CNY, down from 242.38 million CNY in the previous year, representing a decrease of approximately 18.2%[4]. - The net profit after deducting non-recurring gains and losses is expected to be -90.56 million CNY, compared to -74.09 million CNY in the previous year[4]. - The expected non-recurring gains and losses for 2025 are approximately 4.75 million CNY, with specific data to be disclosed in the annual report[7]. - The financial data presented is preliminary and has not been audited by the accounting firm[5]. - The detailed financial results for 2025 will be disclosed in the company's annual report, urging investors to make cautious decisions[8]. Sales Performance - The company reported a slight increase in sales revenue and volume for its product Su Tai Shen during the reporting period[6]. - Revenue from the product Shu Tai Qing has declined due to external environment and industry policy factors, prompting the company to explore multiple channels for market expansion[7]. Marketing Strategy - The company is focusing on marketing efforts for its new polyethylene glycol series products, including "Compound Polyethylene Glycol (3350) Electrolyte Powder (Shu Si Tong)" and "Compound Polyethylene Glycol (3350) Electrolyte Oral Solution (Shu Yi Qing)"[7].

数据显示，中信保诚基金旗下1只基金重仓舒泰神。中信保诚至瑞混合A（003432）四季度增持6万股， 持有股数35.5万股，占基金净值比例为4%，位居第六大重仓股。根据测算，今日浮亏损失约51.83万 元。 中信保诚至瑞混合A（003432）成立日期2016年10月21日，最新规模1.34亿。今年以来收益1.83%，同 类排名6888/8861；近一年收益7.03%，同类排名6921/8126；成立以来收益72.96%。 中信保诚至瑞混合A（003432）基金经理为王睿、朱慧灵。 1月27日，舒泰神跌5.2%，截至发稿，报26.60元/股，成交3.83亿元，换手率3.13%，总市值127.09亿 元。 资料显示，舒泰神(北京)生物制药股份有限公司位于北京市北京经济技术开发区经海二路36号，成立日 期2002年8月16日，上市日期2011年4月15日，公司主营业务涉及主要从事生物制品和部分化学药品的研 发、生产和销售。主营业务收入构成为：注射用鼠神经生长因子(苏肽生)59.17%，复方聚乙二醇电解质 散33.19%，其他7.63%。 从基金十大重仓股角度 朱慧灵累计任职时间301天，现任基金资产总规模2.42亿元 ...